Stock APLI APPILI THERAPEUTICS INC.
Add to a list

Appili Therapeutics Inc. Stock

Stocks

APLI

CA03783R1073

Biotechnology & Medical Research

OTC Markets Traded
Market Closed - Toronto S.E.
Other stock markets
 13:37:26 2026-07-07 EDT 		5-day change 1st Jan Change
0.0150 CAD 0.00% Intraday chart for Appili Therapeutics Inc. 0.00% -40.00%
07-04 Appili Therapeutics Inc. Receives Notice of Termination for Convenience from National Institute of Allergy and Infectious Diseases on Contract for VXV-01 Program CI
06-27 Appili Therapeutics Inc. Reports Earnings Results for the Full Year Ended March 31, 2026 CI

Valuation: Appili Therapeutics Inc.

Market Cap 1.99M 1.4M 1.23M 1.13M 1.05M 134M 2.03M 13.63M 5.29M 65.6M 5.26M 5.14M 228M P/E 2025
-1.62x
P/E 2026 -0.44x
Enterprise Value 14.88M 10.49M 9.2M 8.5M 7.85M 1B 15.18M 102M 39.69M 492M 39.4M 38.54M 1.71B EV / Sales 2025
152,429,607x
EV / Sales 2026 60,946,081x
Free-Float
99.94%
Yield 2025 *
-
Yield 2026 -
* Estimated data More valuation ratios

Chart: Appili Therapeutics Inc.

Dynamic Chart

Latest news : Appili Therapeutics Inc.

07-04 Appili Therapeutics Inc. Receives Notice of Termination for Convenience from National Institute of Allergy and Infectious Diseases on Contract for VXV-01 Program CI
06-27 Appili Therapeutics Inc. Reports Earnings Results for the Full Year Ended March 31, 2026 CI
06-26 Appili Therapeutics Inc. Auditor Raises 'Going Concern' Doubt CI
02-18 Appili Therapeutics announces closing of second tranche of non-brokered private placement RE
02-12 Appili Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
12-18 Appili Therapeutics closes first tranche of non-brokered private placement RE
12-15 The Lundquist Institute and Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 Million Competitive Contract from NIH/NIAID CI
11-13 Appili Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
11-13 Appili Therapeutics Brief: On LIKMEZ (ATI-1501), Says "Building Commercial Momentum in the U.S. Through Re-Launch and Increasing Sales Growth" MT
11-13 Appili Therapeutics Brief: Citing New NIAID Non-Dilutive Funding Award of Up to US $40 Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs MT
11-13 Appili Therapeutics Brief: Reported a Q2 Net and Comprehensive Loss of $1.0 million ($0.01 per share) MT
11-05 Appili Therapeutics Announces $750,000 Private Placement for Working Capital, Drug Development MT
11-05 Appili Therapeutics announces proposed non-brokered private placement RE
More news

Press Releases: Appili Therapeutics Inc.

07-06 Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program AQ
07-03 Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program AQ
06-26 Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results AQ
03-30 Appili Therapeutics to Exhibit at World Vaccine Congress Washington AQ
02-18 Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement AQ
More press releases

Quotes and Performance

6 months-25.00%
Current year-40.00%
More quotes

Course Extremes

1 week 0.01
Extreme 0.01
 0.02
1 month 0.01
Extreme 0.01
 0.02
Current year 0.01
Extreme 0.01
 0.02
1 year 0.01
Extreme 0.01
 0.04
3 years 0.01
Extreme 0.01
 0.08
5 years 0.01
Extreme 0.01
 1.14
10 years 0.01
Extreme 0.01
 1.89
More quotes

Managers and Directors: Appili Therapeutics Inc.

Manager TitleAgeSince
Don Cilla CEO
 Chief Executive Officer 65 2022-10-31
Kenneth Howling DFI
 Director of Finance/CFO 68 2021-11-15
Arthur Baran PRN
 Corporate Officer/Principal - -
Director TitleAgeSince
Juergen Froehlich BRD
 Director/Board Member 70 2020-01-26
Prakash Gowd BRD
 Director/Board Member 62 2023-11-12
Brian Bloom CHM
 Chairman 50 2015-05-06
More insiders

Latest insider transactions

Date Insider Type Main position Quantity % Market Cap.
25-07-15
Brian Bloom
Option

Director

128,674 0.1061%
25-07-15
Brian Bloom
Option

Director

128,674 0.1061%
25-07-15
Brian Bloom
Option

Director

1,189,580 0.9810%
Transaction History

Bio Therapeutic Drugs

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
APPILI THERAPEUTICS INC. Stock Appili Therapeutics Inc.
0.00%0.00%0.00%-50.00% 1.4M
ARGENX SE Stock argenx SE
-0.88%-3.93%+70.49%+125.48% 56.71B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-2.45%-7.83%+63.92%+83.15% 51.3B
INSMED INCORPORATED Stock Insmed Incorporated
+3.27%+8.91%+21.21%+486.76% 25.26B
BIONTECH SE Stock BioNTech SE
-0.81%-0.42%-16.24%-12.47% 23.65B
WUXI BIOLOGICS (CAYMAN) INC. Stock WuXi Biologics (Cayman) Inc.
+3.93%+3.35%+43.09%-2.47% 18.69B
GENMAB A/S Stock Genmab A/S
-0.63%+0.19%+36.89%-26.52% 17.71B
PHARMAESSENTIA CORPORATION Stock PharmaEssentia Corporation
+2.34%+12.50%+224.02%+380.99% 17.7B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. Stock Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
-0.92%+1.58%+35.79% - 14.26B
EXELIXIS, INC. Stock Exelixis, Inc.
-1.70%+3.98%+28.96%+190.57% 14.1B
Average +0.21%+3.61%+50.81%+130.61% 23.94B
Weighted average by Cap. -0.19%+2.20%+57.53%+143.46%
See all sector performances

Financials

2025 2026
Net sales 0.1 0.07 0.06 0.06 0.05 6.78 0.1 0.69 0.27 3.32 0.27 0.26 11.52 0.24 0.17 0.15 0.14 0.13 16.48 0.25 1.68 0.65 8.07 0.65 0.63 28
Net income -2.62M -1.85M -1.62M -1.5M -1.38M -177M -2.68M -18.01M -7M -86.71M -6.95M -6.8M -301M -4.24M -2.99M -2.62M -2.42M -2.24M -286M -4.33M -29.11M -11.31M -140M -11.23M -10.98M -486M
Net Debt 11.07M 7.8M 6.84M 6.32M 5.84M 747M 11.29M 75.95M 29.51M 366M 29.3M 28.66M 1.27B 12.9M 9.09M 7.98M 7.36M 6.8M 871M 13.15M 88.51M 34.39M 426M 34.15M 33.4M 1.48B
* Estimated data More financial data

Company Profile

Logo Appili Therapeutics Inc.
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.
Employees
7
Sector
Biotechnology & Medical Research
More about the company

Quotes

Date Price Change Volume
26-07-07 $0.0150 0.00% 64,000
26-07-02 $0.0150 0.00% 58,300
26-06-30 $0.0150 0.00% 25,000

Delayed Quote Toronto S.E.

More quotes

Income Statement and Estimates

More financial data
  1. Stock Market
  2. Stocks
  3. APLI Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong